Nyxoah S.A. (NYXH)
USD 5.98
(-2.76%)
USD 5.98
(-2.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -43.28 Million EUR | -68.19% |
| 2022 | -27.88 Million EUR | -14.04% |
| 2021 | -24.58 Million EUR | -98.43% |
| 2020 | -10.6 Million EUR | -71.02% |
| 2019 | -6.65 Million EUR | 24.73% |
| 2018 | -8.83 Million EUR | 12.69% |
| 2017 | -10.11 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -11.79 Million EUR | -12.91% |
| 2024 Q2 | -12.7 Million EUR | 4.74% |
| 2023 Q1 | -10.42 Million EUR | -32.04% |
| 2023 Q3 | -9.85 Million EUR | 10.36% |
| 2023 Q2 | -10.99 Million EUR | -5.48% |
| 2023 FY | - EUR | -68.19% |
| 2023 Q4 | -10.39 Million EUR | -5.41% |
| 2022 Q2 | -2.24 Million EUR | 57.13% |
| 2022 Q1 | -5.24 Million EUR | 20.85% |
| 2022 FY | - EUR | -14.04% |
| 2022 Q3 | -8.34 Million EUR | -271.21% |
| 2022 Q4 | -7.89 Million EUR | 5.32% |
| 2021 Q2 | -5.83 Million EUR | -18.04% |
| 2021 Q3 | -7.9 Million EUR | -35.37% |
| 2021 FY | - EUR | -98.43% |
| 2021 Q4 | -6.62 Million EUR | 16.16% |
| 2021 Q1 | -4.94 Million EUR | -57.7% |
| 2020 Q3 | -3.58 Million EUR | -163.48% |
| 2020 Q1 | -1.9 Million EUR | 0.0% |
| 2020 FY | - EUR | -71.02% |
| 2020 Q4 | -3.13 Million EUR | 12.58% |
| 2020 Q2 | -1.36 Million EUR | 28.48% |
| 2019 Q3 | -2.23 Million EUR | -42.28% |
| 2019 Q4 | -1.9 Million EUR | 14.89% |
| 2019 Q2 | -1.57 Million EUR | 0.0% |
| 2019 FY | - EUR | 24.73% |
| 2019 Q1 | -1.57 Million EUR | 0.0% |
| 2018 FY | - EUR | 12.69% |
| 2017 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 5.141% |
| AngioDynamics, Inc. | -14.29 Million USD | -202.869% |
| AtriCure, Inc. | -8.1 Million USD | -433.802% |
| Avinger, Inc. | -16.34 Million USD | -164.811% |
| Azenta, Inc. | 55.15 Million USD | 178.486% |
| BioLife Solutions, Inc. | -45.23 Million USD | 4.315% |
| The Cooper Companies, Inc. | 882.8 Million USD | 104.903% |
| Daxor Corporation | 329.74 Thousand USD | 13227.312% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | -227.974% |
| Femasys Inc. | -13.16 Million USD | -228.686% |
| GlucoTrack, Inc. | -7.09 Million USD | -510.436% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 555.978% |
| Hologic, Inc. | 1.29 Billion USD | 103.339% |
| ICU Medical, Inc. | 307.69 Million USD | 114.068% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 101.808% |
| KORU Medical Systems, Inc. | -9.39 Million USD | -360.509% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 188.357% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -558.329% |
| Innovative Eyewear, Inc. | -6.57 Million USD | -558.329% |
| Masimo Corporation | 236.7 Million USD | 118.287% |
| Microbot Medical Inc. | -10.63 Million USD | -307.053% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 374.474% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 118.703% |
| Nephros, Inc. | -1.37 Million USD | -3038.941% |
| NovoCure Limited | -175.86 Million USD | 75.387% |
| NEXGEL, Inc. | -2.73 Million USD | -1485.568% |
| NEXGEL, Inc. | -2.73 Million USD | -1485.568% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 49.956% |
| OraSure Technologies, Inc. | 76.15 Million USD | 156.837% |
| Pro-Dex, Inc. | 8.33 Million USD | 619.453% |
| Pulse Biosciences, Inc. | -42.36 Million USD | -2.169% |
| Predictive Oncology Inc. | -13.18 Million USD | -228.372% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | -1623.202% |
| QuidelOrtho Corporation | 545.6 Million USD | 107.934% |
| Repligen Corporation | 124.29 Million USD | 134.826% |
| Sanara MedTech Inc. | -289.09 Thousand USD | -14872.829% |
| STAAR Surgical Company | 33.22 Million USD | 230.297% |
| Sharps Technology, Inc. | -8.98 Million USD | -382.006% |
| Utah Medical Products, Inc. | 24.8 Million USD | 274.505% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 118.658% |
| Jin Medical International Ltd. | 3.44 Million USD | 1357.26% |